Treating chronic uremic patients undergoing periodical dialysis
AssigneeSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
InventorClaudio Cavazza
Life of this patent
Estimating the term…
Abstract
The method for the treatment of chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
Claims19
A method of preventing or treating carnitine deficiency in chronic uremic patients undergoing periodic dialysis comprising administering to the patient at the conclusion of the dialysis an effective amount of L-carnitine or of a pharmaceutically acceptable salt thereof.
A method of preventing or treating carnitine deficiency in chronic uremic patients undergoing periodic dialysis comprising administering to the patient at the conclusion of the dialysis into a venous return line after a dialysis session an amount of L-carnitine or of a pharmaceutically acceptable salt thereof effective to restore a level of carnitine in the patent to a pre-dialytic level, and thereafter reducing the amount of carnitine administered to a level sufficient to maintain carnitine levels to the pre-dialytic level.
A method of preventing or treating carnitine deficiency in chronic uremic patients undergoing periodic dialysis comprising administering to the patient at the conclusion of the dialysis into a venous return line after a dialysis session from about 10 to about 20 mg/kg body weight of carnitine, calculated as L-carnitine, or of a pharmaceutically acceptable salt thereof to restore a level of carnitine in the patent to a pre-dialytic level, and thereafter reducing the amount of carnitine administered to a level sufficient to maintain carnitine levels to the pre-dialytic level
Dependencies are inferred from the claim text.